



ASX ANNOUNCEMENT

28 February 2025

Convertible Note Drawdown

28 February 2025 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) wishes to advise that on 27 February 2025 it formally agreed to a \$750,000 (**Special Purchase**) drawdown on its convertible note facility with Obsidian Global GP, LCC, being the facility previously announced to the market on 21 November 2023 (the **Facility**).

The Facility agreement has been amended to enable the Special Purchase drawdown to occur in two stages:

- First Special Purchase – in the amount of \$150,000, with these funds to be received no later than 28 February 2025; and
- Second Special Purchase – in the amount of \$600,000, to be received following lodgement of an applicable prospectus, which is expected to be lodged in the coming days.

-ENDS-

Authorised for release by Steven Notaro, Company Secretary, Cann Group Limited.

For all other information please contact:

Jenni Pilcher
CEO & Managing Director
Cann Group Limited
+61 3 9095 7088
contact@cann grouplimited.com

Steven Notaro
Company Secretary
Cann Group Limited
+61 3 9095 7088
contact@cann grouplimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: www.cann grouplimited.com | www.satipharm.com